Abstract

A collection of clinical (n = 47) and environmental (n = 79) Fusarium isolates were tested against 10 antifungal drugs, including 2 novel imidazoles. Luli-conazole and lanoconazole demonstrated very low geometric mean MIC values of 0.005 and 0.013 mu g/ml, respectively, compared with 0.51 mu g/ml for micafungin, 0.85 mu g/ml for efinaconazole, 1.12 mu g/ml for natamycin, 1.18 mu g/ml for anidulafungin, 1.31 mu g/ml for voriconazole, 1.35 mu g/ml for caspofungin, 1.9 mu g/ml for amphotericin B, and 4.08 mu g/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due to Fusarium species.